OPSEU Pension Plan Trust Fund lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,462 shares of the company’s stock after purchasing an additional 1,640 shares during the period. Johnson & Johnson comprises about 0.8% of OPSEU Pension Plan Trust Fund’s investment portfolio, making the stock its 12th biggest holding. OPSEU Pension Plan Trust Fund’s holdings in Johnson & Johnson were worth $2,594,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Johnson & Johnson by 0.6% during the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after acquiring an additional 1,168,129 shares during the period. Morgan Stanley raised its stake in Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after acquiring an additional 54,563 shares during the period. Nordea Investment Management AB raised its stake in Johnson & Johnson by 88.0% during the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after acquiring an additional 8,062,204 shares during the period. Swiss National Bank raised its stake in Johnson & Johnson by 1.4% during the second quarter. Swiss National Bank now owns 11,304,866 shares of the company’s stock worth $1,589,803,000 after acquiring an additional 157,100 shares during the period. Finally, California Public Employees Retirement System raised its stake in Johnson & Johnson by 8.9% during the third quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after acquiring an additional 864,547 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now directly owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.27% of the company’s stock.
Shares of NYSE:JNJ opened at $146.36 on Friday. The stock has a market capitalization of $385.30 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The company has a 50 day moving average price of $145.51 and a 200 day moving average price of $146.57.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period last year, the firm posted $2.12 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 7.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date of this dividend is Monday, November 23rd. Johnson & Johnson’s payout ratio is 46.54%.
Several equities research analysts have commented on the stock. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Cantor Fitzgerald raised their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $164.93.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: What are gap-down stocks?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.